154 related articles for article (PubMed ID: 31639056)
1. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer.
Park HS; Kwon WS; Park S; Jo E; Lim SJ; Lee CK; Lee JB; Jung M; Kim HS; Beom SH; Park JY; Kim TS; Chung HC; Rha SY
J Immunother Cancer; 2019 Oct; 7(1):268. PubMed ID: 31639056
[TBL] [Abstract][Full Text] [Related]
2. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
3. CD4
Kindlund B; Sjöling Å; Yakkala C; Adamsson J; Janzon A; Hansson LE; Hermansson M; Janson P; Winqvist O; Lundin SB
Gastric Cancer; 2017 Jan; 20(1):116-125. PubMed ID: 26782287
[TBL] [Abstract][Full Text] [Related]
4. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
5. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
[TBL] [Abstract][Full Text] [Related]
6. Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3
Li H; Cao GM; Gu GL; Li SY; Yan Y; Fu Z; Du XH
World J Gastroenterol; 2023 Oct; 29(40):5582-5592. PubMed ID: 37970473
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
9. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
10. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
11. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
12. Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients.
Son SM; Woo CG; Kim DH; Yun HY; Kim H; Kim HK; Yang Y; Kwon J; Kwon M; Kim TY; Kim HD; Koh JY; Park SH; Shin EC; Han HS
Sci Rep; 2020 Aug; 10(1):14293. PubMed ID: 32868848
[TBL] [Abstract][Full Text] [Related]
13. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
14. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
15. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
16. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
17. [Detection of intracellular and extracellular cytokines of CD4+CD25+ regulatory T cells in gastric cancer patients].
Wang LY; Zeng Y; Pan ZZ; Zhu ZH
Ai Zheng; 2007 Mar; 26(3):270-3. PubMed ID: 17355789
[TBL] [Abstract][Full Text] [Related]
18. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
20. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]